Real-world study of Trifluridine/Tipiracil for metastatic colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a real-world treatment with a combination drug called Trifluridine/Tipiracil for people with metastatic colorectal cancer. It aims to see how well it works and how safe it is in everyday medical practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with metastatic colorectal cancer (cancer that has spread to other parts of the body).
- You are willing to use effective birth control (if applicable) and not donate sperm during the study and for 3 months after the last dose.
- You agree to join the study and sign a consent form.
- Your medical history during treatment can be traced.
- Your doctor thinks you may benefit from taking part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for people with advanced colorectal cancer that has spread or come back after initial chemotherapy. It is for those who have already received standard first-line therapy and are now looking for a second treatment option.
This trial tests a chemotherapy drug (trifluridine/tipiracil) in people with metastatic colorectal or gastroesophageal cancer who have a DPD deficiency. DPD deficiency means your body may have trouble breaking down certain chemotherapy drugs, which can lead to serious side effects. This study aims to see if this drug is safe and effective for you.
This trial tests a new schedule of two drugs—bevacizumab and trifluridine/tipiracil—given every two weeks instead of more often. The goal is to reduce severe low white blood cell counts (neutropenia) while still treating advanced colorectal cancer that has not responded to several previous treatments.
This trial tests a combination of two oral cancer drugs, trifluridine/tipiracil and fufuquitinib, as a third-line treatment for people with advanced colorectal cancer. It may be an option if prior treatments have stopped working.
This trial tests a combination of three drugs (irinotecan, TAS-102, and bevacizumab) for people with metastatic colorectal cancer that has already been treated with oxaliplatin-based chemotherapy. The goal is to see if this three-drug combination works better as a second treatment option.
This trial tests whether a new chemotherapy combination (precemtabart tocentecan, with or without bevacizumab) works better than a standard treatment for colorectal cancer that has spread and stopped responding to previous drugs. The goal is to find treatments that help people live longer with fewer side effects.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.